Investigation of bioactivation of ticlopidine using linear ion trap/orbitrap mass spectrometry and an improved mass defect filtering technique.
Ruan, Qian; Zhu, Mingshe.
Chem Res Toxicol
; 23(5): 909-17, 2010 May 17.
Artigo em Inglês | MEDLINE | ID: mdl-20297803
Impact of the CYP2C19 Gene Polymorphism on Clopidogrel Personalized Drug Regimen and the Clinical Outcomes.
Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.
Synthesis of Biologically Active Piperidine Metabolites of Clopidogrel: Determination of Structure and Analyte Development.
Formation, reactivity, and antiplatelet activity of mixed disulfide conjugates of clopidogrel.
Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin.
Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
Significant Improvement of Metabolic Characteristics and Bioactivities of Clopidogrel and Analogs by Selective Deuteration.
Interacção clopidogrel--inibidores da bomba de protões: implicações para a prática clínica.
Enhanced Platelet Response to Clopidogrel in Abcc3-deficient Mice Due to Its Increased Bioactivation.
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.